<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006145</url>
  </required_header>
  <id_info>
    <org_study_id>A3309-012</org_study_id>
    <nct_id>NCT04006145</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of
      elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or
      NASH (nonalcoholic steatohepatitis)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-Blind, Randomized, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in serum low-density lipoprotein cholesterol (LDL-C) at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from Baseline to Week 16 in liver fat fraction (%) as measured by MRI-proton density fat fraction (PDFF)</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from Baseline to Week 16 in total liver fat (mL) as measured by MRI</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 16 in Liver Functions tests</measure>
    <time_frame>Week 16</time_frame>
    <description>Liver function tests include alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyltransferase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 16 in Cholesterol profile</measure>
    <time_frame>Week 16</time_frame>
    <description>Cholesterol profile includes HDL-C, non-HDL-C, and triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 16 in Cholesterol profile</measure>
    <time_frame>Week 16</time_frame>
    <description>Cholesterol profile includes LDL-C/HDL-C ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 16 in serum total bile acids</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>NAFLD</condition>
  <condition>NASH</condition>
  <arm_group>
    <arm_group_label>Elobixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elobixibat 5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat</intervention_name>
    <description>Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).</description>
    <arm_group_label>Elobixibat</arm_group_label>
    <other_name>A3309</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo identical in appearance to active drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Have a current biopsy-confirmed NASH within 6 months of screening or a suspected
             diagnosis of NAFLD/NASH

          -  Screening MRI-PDFF with ≥10% liver steatosis

          -  Fasting serum LDL-C &gt;130 mg/dL at Screening, &gt;110 mg/dL on lipid-lowering medications

        Key Exclusion Criteria:

          -  Body mass index (BMI) &lt;25 kg/m2

          -  Fibrosis-4 index (Fib-4) &gt;2.6

          -  Any of the following laboratory abnormalities:

               1. ALT &gt;5 × upper limit of normal (ULN) or AST &gt;5 × ULN

               2. International normalized ratio (INR) ≥1.3, unless on anticoagulant therapy

               3. Total bilirubin &gt;ULN, except with an established diagnosis of Gilbert's syndrome

               4. Platelet count less than the lower limit of normal (LLN)

               5. Creatinine clearance as calculated by the modification of diet in renal disease
                  (MDRD) estimated glomerular filtration rate (eGFR) equation &lt;60 mL/min

          -  Uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) &gt;9.5%

          -  Clinical hyperthyroidism or hypothyroidism or screening hormone results pointing to
             thyroid dysfunction.

          -  Uncontrolled hypertension

          -  Patients with known intolerance to MRI or with conditions contraindicated for MRI
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials, LLC</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peak Gastroenterology Associates</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Clinical Research, LLC</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guardian Angel Research Center, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

